[{"orgOrder":0,"company":"Genenta Science","sponsor":"Alira Health | Arithmos | Ospedale San Raffaele","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Alira Health | Arithmos | Ospedale San Raffaele","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Alira Health | Arithmos | Ospedale San Raffaele"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"ENEA Tech and Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Infusion","sponsorNew":"Genenta Science \/ ENEA Tech and Biomedical","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ ENEA Tech and Biomedical"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Temferon","moa":"IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genenta Science \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Undisclosed"},{"orgOrder":0,"company":"Genenta Science","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Agreement","leadProduct":"Pembrolizumab","moa":"||IFNAR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genenta Science \/ Genenta Science","highestDevelopmentStatusID":"7","companyTruncated":"Genenta Science \/ Genenta Science"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Genenta Science","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genenta Science \/ Ospedale San Raffaele","highestDevelopmentStatusID":"5","companyTruncated":"Genenta Science \/ Ospedale San Raffaele"}]

Find Clinical Drug Pipeline Developments & Deals by Genenta Science

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The financing will be used to advance their pipeline product Temferon, which is being evaluated for the treatment of methastatic Renal Cell Cancer.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          March 19, 2025

                          Lead Product(s) : Temferon,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : ENEA Tech and Biomedical

                          Deal Size : $21.9 million

                          Deal Type : Financing

                          blank

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Un der the agreement, AGC will support the Genenta to advance their pipeline product Temferon, which is being evaluated for the treatment of methastatic Renal Cell Cancer.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Undisclosed

                          January 09, 2025

                          Lead Product(s) : Temferon,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          PackExpo
                          Not Confirmed
                          PackExpo
                          Not Confirmed

                          Details : Temferon is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                          Product Name : Undisclosed

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          December 04, 2024

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Alira Health | Arithmos | Ospedale San Raffaele

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Temferon is based on ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules. It is being evaluated for metastatic renal cell cancer.

                          Product Name : Temferon

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          October 02, 2024

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Temferon uses ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules via tumor-infiltrating monocytes; it's in phase 1/2 trials for uMGMT glioblastoma.

                          Product Name : Temferon

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          February 08, 2024

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of Glioblastoma Multiforme.

                          Product Name : Temferon

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          July 28, 2023

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of glioma.

                          Product Name : Temferon

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          June 29, 2023

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The amended and restated license agreement reinforces Genenta's long-term strategic relationship with OSR, who contributes unique and valuable expertise to the development of cell-based therapies. Genenta has exclusive worldwide commercial rights to Temf...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          April 03, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Ospedale San Raffaele

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-alpha expression within cancers. Temferon modifies TEMs to release IFN-α inside tumors, rebuilding the immune system and counte...

                          Product Name : Temferon

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 02, 2023

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter has escalated to next planned dose, on basis of no drug-limiting toxicities observed at lower doses, in previous three dose level cohorts.

                          Product Name : Temferon

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          May 04, 2022

                          Lead Product(s) : Temferon

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank